Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCL By Ogkologos - December 6, 2024 693 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the STARGLO study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Should CAR T Cells Be Used Earlier in People with Non-Hodgkin... January 13, 2022 FDA Approval Likely to Change Initial Treatment for Some People with... May 2, 2025 Husband Turns Wife’s Inspiring Poem for Her Daughters into a Book... February 25, 2020 Cancer in My Community: Improving Access to Palliative Care in Indonesia January 13, 2022 Load more HOT NEWS Two Early Studies Show Rapid Antitumour CAR-Mediated Responses, but Often of... Coming together for Zynlonta Study Tests Immunotherapy in People with Cancer and Autoimmune Diseases How Alcohol Increases Your Cancer Risk and What to Know About...
